Working… Menu

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03399539
Recruitment Status : Suspended (FDA and IRB directive to temporarily close to enrollment due to important safety findings)
First Posted : January 16, 2018
Last Update Posted : March 20, 2019
National Cancer Institute (NCI)
Multiple Myeloma Research Foundation
Information provided by (Responsible Party):
Mayo Clinic

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : March 2, 2022
Estimated Study Completion Date : March 2, 2022